Elan Corporation, plc (ELN)
-NYSE 12.10 
0.06(0.50%) 3:16PM EDT - Nasdaq Real Time Price
| Prev Close: | 12.04 |
|---|
| Open: | 12.01 |
|---|
| Bid: | 12.07 x 8800 |
|---|
| Ask: | 12.08 x 176100 |
|---|
| 1y Target Est: | 12.56 |
|---|
| Beta: | 1.25 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 12.00 - 12.11 |
|---|
| 52wk Range: | 9.37 - 14.91 |
|---|
| Volume: | 12,404,604 |
|---|
| Avg Vol (3m): | 5,731,010 |
|---|
| Market Cap: | 6.17B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.07 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Flush With Cash, Elan Goes on a Buying Spreeat Motley Fool(Tue 1:44PM EDT)
- Elan Continues To Make Baffling Strategic Decisionat Investopedia(Tue 1:30PM EDT)
- Elan Proposes Sweeping Transformationat Motley Fool(Tue 7:10AM EDT)
- Theravance pullback on Elan bid a buying opportunity, says Piper Jaffrayat theflyonthewall.com(Tue 7:07AM EDT)
- Biotech Companies: The FDA Doesn't Care About Your Phase 3 Trialsat Motley Fool(Mon, May 20)
- Royalty raises Elan bid, issues ultimatum to shareholdersat Reuters(Mon, May 20)
- Royalty ups Elan bid and issues shareholder ultimatumat Reuters(Mon, May 20)
- Royalty Pharma Raises Bid for a Resistant Elanat New York Times(Mon, May 20)
- InPlay: Elan issues resposne to Royalty Pharma announcement: will assess increased offer of $12.50 per shareBriefing.com(Mon, May 20)
- Elan’s Response to Royalty Pharma AnnouncementBusiness Wire(Mon, May 20)
- Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All CashPR Newswire(Mon, May 20)
- [video] Faber Report: Royalty Pharma to Raise Elan Bidat CNBC(Mon, May 20)
- [video] Faber Report: Actavis to Buy Warner Chilcottat CNBC(Mon, May 20)
- Early Movers: YHOO, CPB, BA, GE & Moreat CNBC(Mon, May 20)
- Elan Announces Proposed Offering of US$800.0 Million in Aggregate Principal Amount of Senior Notes Due 2021Business Wire(Mon, May 20)
Key Statistics
| Forward P/E (1 yr): | 60.40 |
|---|
| P/S (ttm): | 30,703.99 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.07 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.04 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | 74.35 |
|---|
Business Summary
Elan Corporation, plc operates as a biotechnology company in the United States, Ireland, and internationally. The company primarily develops ELND005, an orally bioavailable small molecule in Phase II clinical trial being investigated for multiple ...
View More